E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Sleep-disordered breathing |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Psychological processes [F02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10078294 |
E.1.2 | Term | Obstructive sleep apnoea hypopnoea syndrome |
E.1.2 | System Organ Class | 100000004855 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10040977 |
E.1.2 | Term | Sleep apnoea |
E.1.2 | System Organ Class | 100000004855 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the effect of Montelukast on neurocognition, specifically processing speed measured as Cancellation (Wechsler scales) and NIH toolbox processing speed. |
|
E.2.2 | Secondary objectives of the trial |
• To assess the effect of Montelukast on -adenoid:nasopharynx size -brain MRI -overnight oximetry, -symptoms of sleep-disordered breathing, e.g. snoring -sleep duration and -Pain • To assess side-effects of Montelukast • To assess feasibility of MRI in children aged 3-<8 years.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Aged between 3 and <8 years • Informed consent with assent in accordance with institutional policies and European guidelines; ICF must be signed by patients/guardian • HbSS or HbSβ0 thalassaemia diagnosed by standard techniques (HPLC, IEF, MS or AlkE) • History of Sleep-Disordered Breathing, (i.e. parent-reported any degree of snoring (CHSQ questionnaire) and/or any abnormality on overnight oximetry compared with published data in children of the same age (e.g. nadir SO2<93%; mean SO2<96%)) • In steady state i.e. haemoglobin not decreased by >10% in previous year, no painful crisis requiring opioids for at least 1 month and at least 1 month after any hospital admission • Likely to comply with treatment for 3 months as determined by the local paediatrician or hematologist • Able to speak and understand English
|
|
E.4 | Principal exclusion criteria |
• Other developmental or psychiatric disorders including craniofacial abnormalities, neuromuscular disorder and other chronic conditions. • Patient already on montelukast • Patient has had side effects on or an adverse reaction to montelukast in the past • Presence or history of another hemoglobinopathy or blood dyscrasia • Concomitant treatment with any other leukotriene antagonist within a window period of enrolment • Participation on other SCD/Montelukast trials
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The trial is powered to look at 2 primary outcomes 1. Cancellation (paper-and-pencil test of processing speed and attention from the Wechsler scales) 2. Processing speed on the NIH toolbox
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Baseline before treatment and after 12 weeks of treatment |
|
E.5.2 | Secondary end point(s) |
o NIH toolbox executive function o Duration of Sleep from Children’s Sleep Habit questionnaire (CSHQ) o Symptoms of Sleep Disordered Breathing from Pediatric Sleep questionnaire (PSQ) o Pain burden from sickle module of PEDSQL o AEs & drug side-effects
* Additional secondary endpoints in patients willing to undergo optional additional tests (MRI without sedation (awake/asleep); overnight oximetry):
o Self-rated pain diaries via trial smartphone app o Core MRI endpoints: Multiparametric maps (MPM) for adenoidal and brain size, Volumetrics(T1 MRI), White matter integrity and structural connectivity (DWI),
* Additional MRI endpoints if tolerated:
Perfusion (ASL), Functional Connectivity (rsFMRI), Multiparametric maps (MPM), Oxygen-extraction fraction (TRUST)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Baseline before treatment and after 12 weeks of treatment |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 31 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 31 |